Muse Stem Cell Therapy in Miami: 2026 Trials, Registries & Unknowns

If you are searching for Muse stem cell therapy in Miami, you have probably seen big promises: a “naturally occurring” repair cell, a Nobel-adjacent scientist, trials in Japan, and a price tag that is not small. You have probably also noticed that very few pages tell you where the evidence actually ends.

This guide does that. It explains what Muse cells are, which human trials really exist, what the 2026 registries do and do not tell you, and the long list of questions science has not yet answered. It is written for patients in Miami who want to make a clear-headed decision, not a rushed one.

Is Muse Stem Cell Therapy Proven?

No. Muse cell therapy is still investigational. The human evidence so far comes from a handful of small Japanese early-phase trials (phase 1 and 2) in conditions such as heart attack, stroke, ALS and a rare skin disease. These studies mainly looked at safety and reported that the cells were generally well tolerated, but they were small, often open-label and sponsor-linked, and none has produced the large, long-term, randomized proof needed for approval. No Muse cell product is approved by the U.S. FDA. In 2026 the honest summary is: promising biology, early human data, many unknowns.

What Are Muse Cells?

Muse cells were reported in a 2010 paper by Dr. Dezawa’s group in the journal PNAS. They were identified as a stress-tolerant population inside what looked like ordinary mesenchymal cultures. A key marker is SSEA-3, a surface protein. A 2024 review in Frontiers estimates that Muse cells make up roughly 1% of the cells in a bone marrow aspirate, which is why purifying them is a real manufacturing challenge.

Three features drive the excitement:

1. Targeted homing. Injured tissue releases a signaling molecule called sphingosine-1-phosphate (S1P). Muse cells carry a receptor (S1PR2) that appears to guide them toward it.
2. Reduced lung trapping. Many conventional MSCs get stuck in the lungs after an IV infusion. Muse cells are reported to pass through more easily.
3. Low tumor concern and low immune reaction. In laboratory and animal work, Muse cells have not formed tumors the way embryonic or induced pluripotent cells can, and researchers have proposed immune-privilege features that may let donor cells be used without tissue matching.

These are scientific reports and hypotheses, many from the discovering laboratory and its collaborators. They are exciting, but they are not a guarantee of clinical benefit in a person. For general background on cell types, see our guide to mesenchymal stem cells and the explainer on the science behind Dezawa Muse cells.

Muse Cells vs. MSCs vs. Exosomes

Patients in Miami hear all three words in the same sentence, so here is the plain version.

Our own comparison pages go deeper on Muse cells vs. MSCs vs. exosomes and Muse cell therapy vs. exosome therapy. A common marketing claim is that “nearly every MSC contains Muse cells.” That may be technically true at a very small fraction, but it also means that the label “Muse” depends on how the product is isolated, counted and verified. That is exactly why documentation matters.

The Human Trials: What Has Actually Been Done

Below is what the published and registered human work shows, in plain language. Sample sizes are small on purpose to be honest: that is the reality of this field.

1. Heart attack (acute myocardial infarction)

A first-in-human study of Muse cells given intravenously after a heart attack has been reported by the Japanese team, with an improvement in left ventricular function described in a small number of patients. Later papers refer to this work but add no large dataset. In short: safety signals were encouraging, efficacy is unproven, and there is no randomized phase 3 result.

2. Ischemic stroke (randomized, placebo-controlled)

The best-designed Muse study to date is a randomized, double-blind, placebo-controlled trial of CL2020 in subacute ischemic stroke, published in 2023 and available on PubMed and PubMed Central. It enrolled 35 patients with moderate-to-severe disability (mRS 3 or higher): 25 received CL2020 and 10 received placebo, as one IV dose 14 to 28 days after the stroke, without immunosuppressants. The main purpose was safety at 12 weeks, with efficacy tracked through 52 weeks.

What to take from it:

• It is a real randomized design, which is more than many cell-therapy claims can say.
• It is small. A study of 35 people cannot prove a treatment works or detect rare side effects.
• A phase 2 trial is a step toward answering the question, not the final answer. Read the paper’s own conclusions and limitations (linked above) rather than relying on a clinic’s summary.

3. ALS (amyotrophic lateral sclerosis)

A phase 2 open-label study published in Cell Transplantation in 2023 (abstract here) gave CL2020 intravenously once a month for six doses to 5 patients at a single center. The treatment was reported as highly tolerated without serious side effects. ALSFRS-R scores trended upward at 12 months compared with the 3 months before treatment, but the difference was not statistically significant: three patients declined more slowly, one faster, one unchanged. The authors themselves state that a larger double-blind study is needed.

4. Other early programs

Muse-based products have also been explored in epidermolysis bullosa, spinal cord injury and newborn brain injury in Japan. These are small, early-stage, mostly open-label, and they do not change the overall conclusion: encouraging safety, unproven benefit.

5. Joint, back and “longevity” use

Here the gap is largest. We could find no published randomized trial of Muse cells for knee osteoarthritis, back pain or general anti-aging. Most of the evidence cited for these uses is preclinical (laboratory or animal) or borrowed from MSC research. That does not mean it cannot work. It means it has not been shown.

A quick evidence table

Patient Registries in 2026: What They Are and What They Are Not

Many patients ask whether there is a “registry” for Muse cell patients. There are three different things that people call a registry, and mixing them up is how misleading marketing happens.

1. Trial registries (like ClinicalTrials.gov, Japan’s jRCT and the WHO ICTRP) list planned and ongoing studies, with a unique ID number.
2. Observational outcomes registries collect survey data from people who already received a treatment as routine care. They track what happens; they do not test whether the treatment works.
3. A clinic’s “patient database” or testimonial page, which has no independent oversight.

What is posted in 2026

• An outcomes registry for a Muse cell brand (NCT07645989). As posted on a public mirror of the ClinicalTrials.gov record, it is sponsored by an industry company, is listed as recruiting with a start date of July 1, 2026, and targets 5,000 participants. It is observational: people who already received the product as routine care complete online surveys about symptoms, quality of life and adverse events over up to five years. The listed conditions include osteoarthritis, longevity, wound care and pain. Sites listed are in North Palm Beach and Guadalajara, Mexico. The sponsor’s description also contains strong marketing-style statements about competing products; treat those as claims, not findings. This registry cannot prove the therapy works, because it has no control group and no randomization.
• A traumatic brain injury observational study (NCT07326059). A nonprofit has listed a small observational study of people who independently receive Muse infusions outside the U.S., with an estimated start in 2028 and an estimated enrollment of 10. The record itself notes that clinical evidence in this setting is limited. It is not yet recruiting.

Neither entry is a Miami-based trial, and neither is a phase 3 efficacy study. They show that post-treatment tracking is beginning, which is useful. They do not tell you whether you personally will benefit.

How to check any registry claim yourself

1. Ask the clinic for the exact registry ID (NCT number or jRCT number).
2. Search that ID on ClinicalTrials.gov or jRCT.
3. Confirm the sponsor, status, design and location. Is it interventional or only observational?
4. Check whether the product, dose and cell source in the record match what is being offered to you.
5. Look for posted results and peer-reviewed publications.

If a clinic cannot give you an ID, that is an answer in itself.

What Remains Unknown About Muse Cell Therapy

This is the section most pages skip. Here is the honest list.

1. Does it work, and for whom? Early trials focused on safety. A few hundred patients in randomized, double-blind studies, with predefined endpoints, are still needed for any single condition.

2. What is the right dose and schedule? The stroke trial used a single IV dose; the ALS study used six monthly doses. There is no agreed dose for orthopedic, wound or “longevity” use.

3. How long do effects last? Most reports stop at 12 to 52 weeks. Durable benefit over years is not established.

4. Long-term safety. Short-term tolerability in small groups is not the same as safety over 10 years. Rare events, immune reactions and tumor risk need long follow-up in thousands of people.

5. Do the cells actually engraft or act through signals? Researchers debate whether benefit comes from cells integrating into tissue, from the factors they release, or both.

6. Product standardization. Muse cells are a small share of any starting sample. Different manufacturers may isolate them differently, and the purity, count and viability of a “Muse” product can vary. The clinical-grade product used in Japanese trials is not the same as every product sold elsewhere.

7. Source and regulatory pathway. Whether cells are donor-derived or from your own body, how they are cultured, and which regulator oversees them all affect risk. See our guides on FDA-approved stem cell treatments and exosome FDA status.

8. Independent replication. Much of the published Muse work comes from the discovering laboratory, collaborating Japanese centers and the sponsor. Independent confirmation is still limited.

9. Cost-effectiveness. With no proven outcome, it is hard to say whether any price is “worth it.” See our honest discussion of the economics of stem cell therapy.

The Regulatory Reality in the United States

The FDA regulates most cell-based products as biologics, and it has warned patients repeatedly about unapproved stem cell offerings in its consumer update on stem cell therapies. As of 2026, approved products in this area are limited: umbilical cord blood products for blood-system disorders, and one MSC product (RYONCIL) for a specific pediatric transplant complication. No Muse cell product is FDA-approved, and approved MSC products are not approved for knee pain, anti-aging or neurologic disease.

State law is a separate layer. Miami patients may have read about changes to state rules on certain stem cell uses in orthopedics; our explainers on the state’s orthopedic MSC approval and the new stem cell law cover what that means. A state allowance for a type of use is not the same as FDA approval and does not prove effectiveness. Ask any clinic exactly which products are covered by which rules, and for which conditions.

The International Society for Stem Cell Research also publishes patient guidance, including questions to ask before any stem cell treatment, which is worth reading before you travel or pay a deposit.

How Muse Therapy Is Described at Miami Stem Cell

At Miami Stem Cell in South Miami, Muse-related offerings are described on the clinic’s own pages, including Muse cells, Muse cell therapy in Japan, Muse cell therapy benefits, Muse cell FAQs and Muse exosomes. You can also read about whether Muse stem cells are safe.

When reviewing any clinic’s page, including ours, use the same checklist:

• Does it name the source and manufacturer of the cells?
• Does it cite peer-reviewed studies that match the condition being treated?
• Does it separate what was shown in trials from what is hoped for?
• Does it give the real price and what is included?
• Does it state the regulatory status plainly?

If you want to walk through any of this with a clinician, you can book a free 15-minute consultation. There is no pressure to treat; the goal is to help you understand your options.

How to Read a Muse Cell Study Like a Skeptic

You do not need a science degree to judge the evidence. Five quick checks go a long way, and they apply to any regenerative medicine claim you see online.

1. Check the study phase. Phase 1 asks “is it safe enough to try?” Phase 2 asks “does it show a signal worth testing further?” Phase 3 asks “does it work better than the alternative in a large group?” Every Muse study described above sits in phase 1 or 2. That is not a criticism; it is simply where the field is.

2. Look for a control group. If everyone receives the treatment, improvement could come from natural recovery, the placebo effect, or simultaneous rehabilitation. The stroke trial had a placebo group; the ALS study and most registries did not. Stroke is a good example of why this matters, because many patients recover partly on their own in the first months.

3. Check who paid and who ran it. Industry-sponsored work is not automatically wrong, and academic work is not automatically right. But independent replication is the gold standard, and for Muse cells it is still thin.

4. Look at the endpoint. A trial can show a change in a blood marker or an imaging measure without showing that patients feel or function better. Ask whether the main endpoint was something a patient would care about, such as walking, speaking, pain or independence.

5. Look at how many people dropped out. In small trials, one or two missing participants can swing the result.

When a clinic quotes “studies show,” ask which study, how many people, what phase, and what the primary endpoint was. A good clinician will welcome those questions.

A Simple Timeline of Muse Cell Research

Notice what is missing from the table: a large confirmatory trial and a regulatory approval. That is the main reason this guide uses the word “investigational” throughout.

Why Standardization Matters More Than Most Patients Realize

Because Muse cells are only a small fraction of a bone marrow or tissue sample, the label on the vial matters enormously. Two products sold as “Muse” could differ in several ways: how the cells were collected, whether they were sorted by the SSEA-3 marker or simply cultured, how many cells are in each dose, how many are alive at injection, and whether they were tested for contamination.

In the Japanese trials, the product (CL2020) was manufactured under defined clinical-grade conditions at a stated dose. In the real world, products offered by clinics may come from different suppliers and processes. That is why the questions about product name, manufacturer and documentation in this guide are not optional extras. If you would like background on how cells are collected in general, see our explainer on how mesenchymal stem cells are harvested, and compare the differences between bone marrow and umbilical cord sources.

Source also affects risk. Your own cells (autologous) behave differently from donor cells, and both carry different considerations. Our overview of autologous stem cell therapy is a good place to start.

Practical Tips for Miami Patients

Miami has a large medical community, a lot of regenerative medicine advertising, and plenty of visitors who travel here for treatment. A few local-minded tips can protect you.

• Do your homework before you travel. If you are coming from another city or country, request documents by email first and review them at home, not in the waiting room.
• Plan follow-up. A treatment is only part of the story. Make sure you know who will see you after the procedure, especially if you live far from South Miami, and how to reach someone quickly if you feel unwell.
• Bring your records. MRI reports, lab results, medication lists and prior treatment notes help a clinician judge whether you are a reasonable candidate at all.
• Beware of urgency. “Limited supply” and “price goes up Friday” are sales techniques, not medical reasons.
• Compare more than one opinion. An orthopedist, neurologist or cardiologist who knows your history can tell you what established options remain, and what a cell therapy might realistically add.
• Keep your own record. Save the product name, lot number, date, dose and the physician’s name. If a registry later asks for outcomes, you will have what you need.

If your main concern is a joint problem, read how stem cell therapy compares across common conditions and what long-term results can look like before deciding whether an investigational option is even necessary.

Realistic Expectations: What a Good Outcome Looks Like

Hype tends to describe outcomes as dramatic. Real regenerative medicine outcomes, when they occur, are usually modest and gradual. If someone offers Muse therapy, a responsible conversation should define success in advance. For example: “We will reassess pain and function at 3 and 6 months using the same questionnaire. If there is no meaningful improvement, we will not repeat the treatment and will review other options.”

Setting that expectation protects you in two ways. It keeps you from paying for repeat treatments without evidence of benefit, and it creates a clear point at which you and your physician decide together whether to continue. A clinic that is confident in its approach should be comfortable with that kind of plan.

Who Might (and Might Not) Be Considering Muse Therapy

People who sometimes explore it:

• Adults with chronic joint or tissue problems who have tried conventional care and want to understand regenerative options.
• Patients curious about advanced options who accept that the therapy is investigational.
• People who understand they may be paying out of pocket for something that may not work.

People who should pause or get a second opinion:

• Anyone being told a condition (such as stroke, ALS, heart disease or cancer) can be “reversed.”
• People with an active or recent cancer diagnosis, pregnancy or breastfeeding, uncontrolled infection or bleeding disorders, unless cleared by their physician.
• Anyone being asked to pay a large deposit the same day.
• Anyone who is told to stop evidence-based care, such as stroke rehabilitation, cardiology care or ALS-approved therapy.

If your problem is a painful knee, shoulder or back, many evidence-based non-surgical options exist, and we describe them in guides such as non-surgical knee pain options and stem cell therapy for arthritis. A conversation about Muse cells should come after you understand the more established choices, not before.

Questions to Ask Before Any Muse Cell Treatment in Miami

Print this list and bring it to your appointment.

1. What is the exact product? Name, manufacturer, cell source (donor or your own) and lot documentation.
2. How is a “Muse” cell defined and verified? Which marker, what percentage, and who tested it?
3. Which regulator and rule covers this product and this condition?
4. Is there a registered study (with an ID) for my condition? What phase, what size, what results?
5. What is the evidence in people, not animals or cells? Please show me the paper.
6. What are the known and unknown risks? Infusion reactions, infection, immune reactions, unknown long-term effects.
7. What outcome should I expect, and when would we call it a failure?
8. What does it cost in total, including repeat doses, follow-up and any extra visits?
9. Who is the supervising physician, and what are their credentials?
10. What happens if something goes wrong, and where would I be treated?
11. Will my results be tracked or reported in a registry, and can I see the data?

Cost, Insurance and Value in Miami

Muse-based treatments are generally not covered by health insurance, because they are investigational. Pricing varies widely by clinic, product, dose and number of sessions, and published prices should be confirmed directly. Our pages on average stem cell therapy cost, stem cell therapy cost in Miami and nearby and how to choose a treatment center explain what drives costs and what a fair quote should include.

A useful rule: the less the evidence, the more reasonable it is to ask for transparent pricing, a written plan and a clear refund or follow-up policy. If you cannot see what you are paying for, you cannot judge its value.

Safety: What Is and Is Not Known

Based on the trials above, short-term IV administration of the Japanese clinical-grade product was generally well tolerated, with no serious treatment-related problems reported in the small ALS study. That is reassuring, but it has limits:

• Trials were small. Rare side effects can go unseen in a few dozen people.
• Follow-up was short compared with the decades some conditions last.
• Products, doses and routes differ from what is sold elsewhere.
• Any cell therapy carries general risks: infection, reaction to the infusion, and the unknown.

For general safety principles across cell therapy, see is stem cell therapy safe and the overview of downsides to consider. Report any unexpected symptoms after treatment to your physician right away.

What to Watch in 2026 and Beyond

Here is what would genuinely change the picture for Muse cell therapy:

• Larger randomized trials (phase 2b/3) in one condition, with preregistered endpoints.
• Independent replication outside the discovering group and sponsor.
• Long-term follow-up of the Japanese trial patients.
• Published results from the outcomes registries, with transparent analysis (including negative results).
• Product standards that let you verify what is in the syringe.
• Clear regulatory decisions in the U.S. and elsewhere.

Until then, the responsible position is curiosity without certainty. You can follow the field by setting alerts on ClinicalTrials.gov and the WHO ICTRP for “Muse cells” and “CL2020,” and by reading our mesenchymal stem cell clinical trials overview for context on how long approvals typically take.

Frequently Asked Questions

Is Muse stem cell therapy available in Miami?

Clinics in Miami may describe Muse-related offerings, but the therapy is investigational and no Muse product is FDA-approved. Ask for the product name, source, regulatory status and any registered study before deciding.

Are there Muse cell clinical trials in 2026?

Yes, but small ones. The best human data come from early Japanese trials (heart attack, stroke, ALS and others). In 2026 an observational outcomes registry was posted as recruiting, and a small observational brain-injury study is listed as not yet recruiting. Check ClinicalTrials.gov and jRCT for current status.

Is the Muse cell registry the same as a clinical trial?

No. The posted registry tracks survey outcomes from people who already received treatment. It has no control group, so it cannot prove effectiveness.

Does Muse cell therapy work for knee pain or arthritis?

No published randomized trial shows that it does. Evidence for joint use is mostly preclinical or extrapolated from MSC research, so any benefit is unproven.

Is Muse cell therapy safe?

Early trials reported good short-term tolerability in small groups. Long-term safety is not established, and any cell therapy has risks.

What is the difference between Muse cells and regular stem cells?

Muse cells are a marker-defined subset (SSEA-3 positive) found among MSC-like cells, reported to home to injured tissue and avoid lung trapping. Regular MSCs are a broader, more variable mix.

Is Muse cell therapy FDA approved?

No. No Muse cell product has FDA approval for any condition.

How much does Muse cell therapy cost in Miami?

Prices vary by clinic and protocol, and insurance generally does not cover investigational treatment. Ask for a written, itemized quote that includes follow-up.

Can Muse cells cure stroke, ALS or heart disease?

No. Early trials examined safety and did not demonstrate a cure. Anyone promising a cure should be treated with caution.

How do I verify a clinic’s Muse cell claims?

Ask for the registry ID, product documentation and published papers, then confirm them yourself on ClinicalTrials.gov, jRCT and PubMed.

Should I stop my current treatment to try Muse cells?

No. Do not stop evidence-based care without your physician’s guidance.

Bottom Line: Hope, Held Honestly

Muse cells are one of the more interesting ideas in regenerative medicine. The biology is thoughtful, and the early Japanese trials suggest short-term tolerability. But in 2026 the human evidence is small, the long-term data are missing, and the clinical benefit is unproven. If you are considering Muse stem cell therapy in Miami, treat it as an informed choice about an investigational treatment, not a guaranteed fix.

The best next step is a calm conversation with a physician who will show you the evidence, name the unknowns and discuss alternatives. At Miami Stem Cell in South Miami, you can book a free 15-minute consultation or contact us to ask any of the questions in this guide. You can also learn more about our team before you decide.

Disclaimer: Individual results vary. This is general information, not medical advice.